Apolipoprotein B, diabetes and medical consensus

Annals of Clinical Biochemistry

Volumn 47, Issue 1, 2010, Pages 2-3

  Sniderman, Allan D ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONSENSUS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; EDITORIAL; HEART DISEASE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TREATMENT FAILURE;

ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; CLOFIBRIC ACID; CONSENSUS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; RISK FACTORS; TREATMENT FAILURE;

EID: 75149177249     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2009.200918     Document Type: Editorial

References (15)

1. Katulanda GW, Katulanda P, Adler AI, et al. Apolipoproteins in diabetes dyslipidemia in South Asians with young adult onset diabetes - distribution, associations and patterns. Ann Clin Biochem 2010;47:29-34
2. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Erratum in: Lancet 2006;366:1415 and 1520. Lancet 2005;366:1849- 61
3. Barter PJ, Ballantyne CM, Carmena R, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006;259:247-58
4. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001;135:447-59
5. Sniderman AD, Zhang Z, Cianflone K. Divergent responses of the liver to increased delivery of glucose or fatty acids: implications for the pathogenesis of type IV hyperlipoproteinemia. Atherosclerosis 1998;137:291-301
6. Stettler C, Suter Y, Allemann S, et al. Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up. J Intern Med 2006;260:272-80
7. Sniderman AD, Lamarche B, Tilley J, et al. Hypertriglyceridemic hyperapoB in type 2 diabetes. Diabetes Care 2002;25:579-82
8. McPherson R, Frohlich J, Fodor G, et al. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27
9. McAlister FA, van Diepen S, Padwal RS, et al. How evidence-based are the recommendations in evidence-based guidelines? PLoS Med 2007;4:1325-32
10. Sniderman AD, Furberg CD. Why guideline-making requires reform. J Am Med Assoc 2009;301:429-31
11. Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines [Editorial]. J Am Med Assoc 2009;301:868-9
12. Choudhry NK, Stelfox H, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. J Am Med Assoc 2002;287:612-7
13. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS2: Joint British Societieś guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:v1-52
14. Sniderman AD. Apolipoprotein B in the therapy of atherogenic dyslipoproteinaemias. In: Tonkin AM, ed. Therapeutic Strategies in Lipid Disorders. Oxford: Clinical Publishing, 2009:43-57
15. Parish S, Peto R, Palmer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholsterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009;30:2137-46